Q-omics provides the consensus-scored DLGAP5 profile across patient tissues and cancer cell-line models. DLGAP5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DLGAP5 is differentially expressed in 18, with the highest sampling consensus in HNSC. Additionally, DLGAP5 protein abundance shows 27,870 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, HNSC, and LUAD as cancer lineages where DLGAP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLGAP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLGAP5 survival associations across molecular data types. DLGAP5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLGAP5 RNA expression–survival associations across cancer types. High DLGAP5 expression shows unfavorable associations in KIRP, ACC, MESO, UVM, KICH and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DLGAP5 RNA expression.
This table summarizes DLGAP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DLGAP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLGAP5 shows higher tumor expression in HNSC, BLCA, KIRP, KIRC, LUSC and LUAD. The HNSC box plot shows higher DLGAP5 RNA expression in tumor versus normal tissue (log2 FC = +2.273, t-test p < 0.001).
This table shows molecular features associated with DLGAP5 in patient tissues and cancer cell lines. In patient samples, DLGAP5 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DLGAP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
